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Introduction Unresectable stage III nonsmall cell lung cancer (NSCLC) continues to 
have dismal 5-year overall survival (OS) rate. However, a subset of the patients treat-
ed with chemoradiation show significantly better outcome. Prediction of treatment 
outcome can be improved by utilizing machine learning tools, such as cluster analysis 
(CA), and is capable of identifying complex interactions among many variables. We 
have utilized CA to identify a cluster with good prognosis within stage III NSCLC.
Materials and Methods Retrospective analysis of treatment outcomes was done for 
92 patients who underwent chemoradiation for inoperable locally advanced NSCLC from 
2012 to 2018. Using various patient- and treatment-related variables, an exploratory 
factor analysis was performed to extract factors with eigenvalue > 1. An  appropriate 
number of homogeneous groups were identified using agglomerative hierarchical clus-
ter analysis. Further K-mean cluster analysis was applied to classify each patient into 
their homogeneous clusters. The newly formed cluster variable was used as an indepen-
dent variable to estimate survival over time using Kaplan–Meier method.
Results With a median follow-up of 18 months, median OS was 14 months. Using 
CA, three prognostic clusters were obtained. Cluster 2 with 36 patients had a median 
OS of 36 months, whereas Cluster 1 with 34 patients had a median OS of 20 months 
(p = 0.004).
Conclusion A cluster could thus be identified with a relatively good prognosis with-
in stage III NSCLC. Using CA, we have attempted to create a model which may pro-
vide more specific prognostic information in addition to that provided by tumor node 
metastasis-based models.
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Introduction
The most frequent cause of cancer-related mortality world-
wide remains to be lung cancer despite progress made in all 
oncological modalities involved in its management. Nearly 
85% of all lung neoplasia are classified as nonsmall cell lung 
cancer (NSCLC)1 of whom about one-third are diagnosed in 
a locally advanced stage.2 Concomitant chemoradiotherapy 
(CCRT) is the established standard of care for unresectable 
stage III disease with evidence of better results compared 
with either modality used alone or sequentially.3 Despite the 
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dismal 5-year overall survival (OS) rate of 15 to 35% for stage 
IIIA and 5 to 10% for stage IIIB,4 a subset of patients in these 
stages show significantly better OS. Conventional patient, 
tumor, and treatment related parameters often do no cor-
relate with the survival outcome, largely due to complex 
interactions between tumor biology, tumor microenviron-
ment, radiation dosimetry, and patient-related variables.
Prediction of treatment outcome can be improved by 
utilizing machine learning (ML) tools capable of identifying 
complex interactions among variables. Of the many such 
tools available, cluster analysis (CA) provides a potential 
relationship and constructs a systematic structure in large 
number of variables and observations. K-means clustering is 
an unsupervised learning algorithm that tries to cluster data-
based on its similarity. We have utilized K-mean CA to iden-
tify a cluster with good prognosis within unresectable stage 
III NSCLC with significantly better overall survival.
Materials and Methods
Retrospective analysis of treatment outcomes was done for 
patients who underwent definite chemoradiation upfront 
or sequentially after neoadjuvant chemotherapy (NACT) for 
inoperable locally advanced NSCLC, adenocarcinoma (AC), 
and squamous cell carcinoma (SCC) from 2012 to 2018.
Patients with small cell or histology other than AC or 
SCC, history of previous thoracic radiotherapy and presence 
of a second primary were excluded from the study. All the 
patients were restaged using the latest eighth edition of 
American Joint Commission on Cancer (AJCC).5
Patient- and treatment-related data were retrieved from 
hospital medical records, available in the form of hospital 
case files, electronic medical records, and radiotherapy cards. 
Patients or their caregivers were contacted telephonically for 
obtaining the latest survival status.
Statistical Analysis
Age has been summarized via mean and standard deviation 
(SD), and radiotherapy dose and overall treatment time by 
median and interquartile range (IQR), and categorical vari-
ables via frequencies and percentages (►Table 1).
We, first explored any underlying factor structure 
between the study variables (age, gender, comorbidity, 
positron emission tomography-complete response, radio-
therapy dose, overall treatment time (OTT), radiotherapy 
technique, and staging). For this purpose, exploratory fac-
tor analysis was performed to extract factors using oblique 
rotation (direct oblimin, which assumes correlated factors), 
with eigenvalue > 1 criterion. A particular variable loaded a 
factor if the value of the loading was highest for that factor. 
Between variables’ correlation, matrix was initially visually 
inspected for extreme multicollinearity. Subsequently the 
Kaiser–Meyer–Olkin test was performed to assess the ade-
quacy of data for factor analysis (test values of >0.5 as accept-
able), and significance of Bartlett’s test (testing the null 
hypothesis that the correlation matrix is an identity matrix).6 
Sensitivity analysis was also done to check any variations 
by considering orthogonal varimax rotation which does not 
assume correlated factors. Next, agglomerative hierarchical 
cluster analysis was performed using Ward’s minimum vari-
ance method to identify the appropriate number of homo-
geneous groups of patients based on the same set as in the 
factor analysis.7 Then, these identified numbers were used in 
the K-mean cluster analysis to classify each patient into their 
homogeneous clusters. The newly formed cluster variable is 
used as independent variable to estimate survival over time 
using Kaplan–Meier method and Cox’s model was used to 
estimate relative hazards (hazard ratio [HR] with 95% con-
fidence interval [CI]). As a complementary analysis, a Cox’s 
model was also constructed using full set of predictor vari-
ables to understand their independent effect on survival.
Results
Of the 152 patients presenting to the department of radia-
tion oncology for definite radiotherapy, data of 92 patients 
who completed their prescribed treatment and presented 
for the first follow-up was analyzed for descriptive statistics 
(►Fig. 1).
Of the 92 patients who received definite chemoradiation 
for unresectable locoregionally advanced NSCLC, 82.6% were 
males. Among the patients, 45.7% had AC while the remain-
ing had SCC. The mean dose of radiation was 60.84 Gy (50–
70 Gy). Conformal techniques, such as intensity modulated 
radiotherapy (IMRT) or image guided radiotherapy (IGRT), 
were employed in the treatment of 72.8% of the patients. The 
mean OTT in the 92 patients analyzed for survival outcomes 
was 90.9 days (range: 40–373 days). Other treatment related 
characteristics have been shown in ►Table 1.
Median follow-up for all patients was 18 months 
(SD ± 11.5; range 3–59 months). At last follow-up, among 92 
patients, 27 (30.5%) patients were alive without disease, 22 
(26.8%) were alive with disease, and 37 (42%) patients had 
died with disease. Median recurrence free survival (RFS) and 
OS were 14 months and 22 months, respectively and 2-year 
RFS and OS were 14.4 and 53.3%, respectively, across all the 
stages (►Fig. 2).
Cluster 2 comprising of 36 (39.1%) patients treated with 
IMRT/IGRT, up to a mean dose of 64 Gy (range: 62.3–65.9 Gy) 
and with a mean OTT of 49 days (range: 45.3–90.8 days), had 
a median OS of 36 months, whereas, cluster 3 comprising of 
22 (23.9%) patients treated with conventional  radiation tech-
niques (two-dimensional [2D]), up to a mean dose of 58 Gy 
(range: 53.5–63.7 Gy) with a mean OTT of 76 days (range: 
44–146 days), had a median OS of 19 months (p = 0.000). 
We could thus identify a cluster with good prognosis within 
stage III where an adequate radiation dose (60–66 Gy) using 
an improved radiation technique delivered in shorter OTT 
(<90 days) was associated with better overall survival (►Fig. 3).
Discussion
The current standard of care in unresectable stage III 
NSCLC patients is curative-dose radiotherapy along with 
platinum-based chemotherapy. However, only 15 to 30% 
of patients survive at 5 years, corresponding to a median 
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survival of approximately 28 months.2 Even with the addition 
of systemic therapy after achieving locoregional control with 
chemoradiotherapy (CRT), median survival ranges from 18 to 
23 months.8 PACIFIC study that compared consolidation using 
durvalumab (a human Ig [immunoglobulin] G1 monoclonal 
antibody that blocks PD-L1 binding to PD-1 and CD80) with 
placebo after concurrent chemoradiation in patients with 
stage III, unresectable NSCLC, demonstrated a 24-month OS 
rate of 66.3% in favor of durvalumab. At a median follow-up 
of 25.2 months, the median OS had not been reached at the 
time of publication of the results.9 Thus a new standard of 
care has been established for unresectable NSCLC.
Table 1  Patient and treatment characteristics
Parameters n Mean or percentage SD Range
Age (y) 92 60.73 (95% CI: 58.7–62.6) 9.343 39–83
Gender
Male 76 82.6
Female 16 17.4
Comorbidity
Yes 43 46.7
No 49 53.3
Histology
ACC 42 45.7
SCC 50 54.3
Stage
IIIA 13 14.1
IIIB 22 23.9
IIIC 57 62.0
Radiation dose 92 60.84 (95% CI: 59.36–61.6) 4.89 50–70
CT timing
NACT 47 51.1
CCRT 45 48.9
NACT cycles (n = 47)
≤3cycles 29 61.7
>3cycles 18 38.3
CT regimen for NACT
Platinum + taxane 23 32.9
Platinum + etoposide 23 32.9
Platinum + gemcitabine 7 10.0
Platinum + pemetrexate 11 15.7
Others 6 8.5
CCRT (n = 45)
≥4 cycles 18 40
<4 cycles 27 60
TTT (d) 92 46.9 (95% CI: 45.9–48.0) 5.1 38–66
OTT (d) 92 90.9 (95% CI: 79.2–102.8) 56.9 40–373
RT technique (n = 92)
2D technique 25 27.2
IMRT/IGRT 67 72.8
Abbreviations: 2D, two-dimensional; ACC, adenocarcinoma; CCRT, concurrent chemoradiotherapy; CT, chemotherapy; IMRT/IGRT, intensity modulat-
ed radiotherapy/image guided radiotherapy; NACT, neoadjuvant chemotherapy; OTT, overall treatment time from initiation of any treatment till end of 
treatment; RT, radiotherapy; SCC, squamous cell carcinoma; SD, standard deviation; TTT, total duration of radiation.
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There has been an attempt at finding the prognostic and 
predictive factors for locoregionally advanced unresect-
able NSCLC which may help in proper patient selection for 
any form of aggressive therapeutic approach to maximize 
the benefits of treatment in an otherwise dismal scenario. 
Age, gender, performance status, weight loss in the period 
of 3 months before diagnosis, baseline hemoglobin value, 
normal leukocytosis and normal neutrophil count, lactate 
dehydrogenase (LDH) level, hypercalcemia, hypoalbumin-
emia, tumor dimension, and involved lymph node burden 
are some of the known prognostic factors in NSCLC.10,11 Prog-
nostic classifications have been attempted based on gene sig-
natures in resected specimen such as the 15-gene signatures, 
independent from stage with an overall HR of 15.02 (95% CI: 
5.12–44.04) with consistent results in stages I and II.12
However, till date, a correlation between the above 
mentioned and many other possibly unknown factors has 
not been established with varied survival outcomes for 
patients within a given stage. Clearly, better models based 
on early assessment of response after definite CRT are 
needed to predict outcome, in time for treatment intensifi-
cation with additional radiation, early addition of systemic 
therapy, or application of a different treatment modality.
With an ever-increasing number of patients with locore-
gionally advanced NSCLC, usually not amenable to surgery, 
the data, required to generate prognostic models for risk 
stratification and treatment intensification has been grow-
ing exponentially, making it imperative to utilize the applica-
tions of ML. ML has the potential to change the way radiation 
oncologists follow patients treated with definitive radiother-
apy. It is a computerized approach to identify complex math-
ematical associations within a set of observational data. It is 
also an application of artificial intelligence (AI) that provides 
systems the ability to automatically learn and improve from 
experience without being explicitly programmed. Further, 
ML may be supervised (prediction, classification, etc.), unsu-
pervised (clustering, probability distribution estimation, 
etc.), or reinforcement learning (robot, chess machines, etc.). 
Many questions in oncology can be answered through ML 
algorithms that aid in decision making in an era of individu-
alized care plans. Within radiation oncology, some work has 
been done to model individual radiation sensitivity to indi-
vidualize and adapt therapy.13
Further, in the field of radiation for malignancy of lung, 
early work was confined to predict tumor motion and pre-
dicting the need for replanning.14 Deep neural networks have 
been used to predict the need for treatment adaptation for 
lung patients.15 Evaluation of 32 clinical features per patient 
in a cohort of 203 stages II and III unresectable NSCLC patients 
treated with definitive chemoradiation using ML established 
Fig. 1 Patient selection criteria and selection of variables for cluster analysis. CCRT, concurrent chemoradiotherapy; NSCLC, nonsmall cell lung 
cancer; RT, radiotherapy.
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random forest as an accurate method to identify known and 
new predictors of symptomatic radiation pneumonitis.16
Analysis of our institute’s data of 92 unresectable stage 
III NSCLC patients who underwent definite chemoradiation 
revealed a median OS of 26 months and a 2-year OS of 53.3%, 
consistent with the known survival rates in other series.2 
This cohort of patients belonged to different stage subgroups 
within stage III (►Table 1), treated with different radiother-
apy techniques (at the treating physician’s discretion, avail-
ability of technology, or patient related logistic constraints), 
varying tumor doses, over a range of treatment time and 
variable positron emission tomography (PET) response after 
CRT. Using multivariable Cox’s regression model, the impact 
of individual variables on survival outcome could be calcu-
lated as shown in ►Table 2.
However, the correlation between these independent vari-
ables and its impact, if any, on survival required the appli-
cation of ML tools. We therefore used a clustering method 
available with SPSS, namely, cluster analysis to derive prog-
nostic groups within stage III. CA is a multivariate method 
which aims to classify a sample of patients (or objects) on 
the basis of a set of measured variables into several differ-
ent groups such that similar patients are placed in the same 
group. K-means clustering is a nonhierarchical method of 
CA in which the desired number of clusters is specified in 
advance and the “best” solution is chosen. It tends to be used 
when large datasets are involved.17
The ML tool, utilizing eight variables as input, arrived at 
three prognostic clusters.
Cluster 2 having 36 patients, all of whom had stage IIC 
NSCLC, were treated with conformal advanced techniques 
to a dose of >60 Gy and completed their treatment within 
90 days. This cluster had a median OS of 36 months which 
was significantly better than that of patients in cluster 3 
(p = 0.000) and cluster 1 (p = 0.004) with similar stage but 
different treatment parameters. This was corroborated by the 
Cox model (►Table 3).
More recently, early tumor shrinkage during the course of 
concurrent chemoradiation has been proposed as a prognostic 
factor in stage III.18 An extensive review of application of ML 
Fig. 2 Kaplan–Meier estimate for OS of 92 patients. OS, overall survival.
61Identifying Prognostic Groups Using Machine Learning Tools Pahuja et al.
Asian Journal of Oncology Vol. 5 No. 2/2019
in radiotherapy for NSCLC has been published, approaching 
the radiotherapy process from a workflow perspective, iden-
tifying specific areas where a data-centric approach using ML 
could improve the quality and efficiency of patient care. While 
touching upon nearly every aspect from patient assessment, 
simulation, planning, quality assurance, treatment delivery to 
follow-up, it serves as a guide for clinicians to discuss issues 
that must be addressed in a timely manner, outside the con-
ventional factors.19 But there is a paucity of data establishing 
radiation dose and technique as prognostic factors in a scenario 
where radiation forms the backbone of treatment and outcome.
RTOG 0617 trial, comparing 60 Gy with 74 Gy, showed a 
significantly lower survival in the high-dose arm,20 conflict-
ing with the results of some prospective studies suggesting 
better local control and higher survival rates with higher 
radiation doses.21,22 The unexpected findings of RTOG 0617 
have been attributed to prolonged OTT and increased heart 
toxicity in the high-dose group. A decrease in tumor control 
probability of 1.6% per day after a 6-week duration of radi-
ation therapy23 and a 2.0% increase in the risk of death for 
each day of prolongation in therapy24 have been published.
Ours being a retrospective analysis, with a wide range of 
doses delivered (40–70 Gy), over a wide range of OTT, using 
different techniques of radiation delivery (as per the treating 
physician’s discretion), it would have been difficult to reach 
a definite conclusion with conventional statistical methods. 
However, with the help of CA, the same heterogeneity could 
be utilized to conclude that not only the total dose but the 
technique used to deliver the same and the duration in which 
it is delivered have an impact on the survival outcome.
A multivariate predictive model, using data from 548 
patients with stage III NSCLC, consisting of age, gender, per-
formance status, overall treatment time, equivalent radiation 
dose, number of positive lymph node stations, and gross-tu-
mor volume has been envisaged as a first building block for 
a decision support system to predict survival probability for 
an individual patient with stage III NSCLC.25 This model was 
based on patients treated with three-dimensional CRT or 
IMRT, therefore predictions for patients treated with other 
techniques were not possible. In the present study, we have 
been able to incorporate treatment technique that ranged 
from 2D to IGRT, in the model.
Fig. 3 Kaplan–Meier estimate showing significantly better overall survival for cluster 2 compared with clusters 1 and 3.
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Limitations
In addition to the retrospective nature of the study, other lim-
itations include small sample size and lack of external valida-
tion. However, this is a real-world data, highlighting treatment 
heterogeneity, in the absence of any randomization. Using 
cluster analysis, we have attempted to create a model which 
may provide clinicians with more specific prognostic informa-
tion in addition to that provided by tumor node metastasis 
(TNM)-based models.
Conclusion
Apparently, a homogenous group according to the TNM stag-
ing system, patients with stage III NSCLC forms a heteroge-
neous group, as reflected in the survival outcome. Instead of 
focusing on a handful of variables in individual studies, large 
databases should be integrated to design prediction models.
While still in its stage of infancy, we envisage that data 
sharing together with machine learning tools can provide 
something much better than conventional statistical meth-
ods in the near future.
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